Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ward Knutson who wrote (7221)	11/22/1999 2:33:00 PM
From: Vector1	Read Replies (2) \| Respond to of 9719

Ward and David, I don't have much time now but a couple of thoughts. First my most recent action was to reduce my MOGN position. The stock is now hovering around 13-14. David is quite correct I like the Salagen rev but at $14 MGI needs to be sucessful to make this stock compelling. With limited information on MGI 114 a lot of this is gut feel and certainly I can be wrong. I have many times in the past. However, I do know that MGI 114 has toxicity issues and while it clearly has an effect on shrinking tumors in some patients the early results are not overwhelming and the mechanism of action is not known (although there are theories). I admit its early and some of the phase IIs may yet present compelling evidence. However one thing I know a little about is the hunger that phama has for approvable anti-cancer agents. With compeling results Blitzer could cut a good deal now. In addition the company's R&D spend is going to increase. Even a multicenter phase III for a single indication is very expensive and more than the company can afford without issuing debt or equity. Hey while we are at it why hasn't this company been able to get analyst coverage. Early on when the stock was in single digits I looked at it as a buying opportunity. Maybe it still is. Finally IMO shrinking primary tumors in metastatic disease may be a false endpoint. I have said before that Pancreatic Cancer is a systemic disease. By the time it is discovered the cancer has already likely spread. The question will be whether MGI can increase survival. Based on what I have read we do not know yet. V1